Trump executive order accelerates psychedelic drug development with priority review vouchers, funding and expanded right-to-try
President Trump signed an executive order that aims to speed the development and approval of psychedelic medicines.
The order directs the FDA to issue priority review vouchers, expands right-to-try pathways for ibogaine, allocates $50 million in ARPA-H funding, and authorizes the DEA to expedite scheduling of FDA‑approved psychedelics.
Recent FDA actions reflect this momentum, including priority review vouchers to Compass and Usona for psilocybin programs, a voucher to Otsuka for methylone, and clearance for DemeRx’s noribogaine trial.
The order also launches a collaboration with the Veterans Affairs to explore psychedelic therapies for veterans, indicating broader governmental support.
This writeup was produced by pharmadog from original reporting by STAT.
Original headline: “Opinion: Trump’s executive order on psychedelics is the right move. But is my field ready for it?”
read at STAT ↗
comments(0)
5-min edit window · permanent after that